Showing results (1101-1110 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 8, 2010
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancerTakashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, et al.
Investigational New Drugs|July 9, 2010
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosisFederica Servida, Daniele Lecis, Cinzia Scavullo, et al.
Investigational New Drugs|July 15, 2010
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation statusFrancesca Buontempo, Tulin Ersahin, Silvia Missiroli, et al.
Investigational New Drugs|August 10, 2010
K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cellsYuen-Keng Ng, Elaine Yue Ling Wong, Cecilia Pik Yuk Lau, et al.
Investigational New Drugs|August 11, 2010
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinomaYing Yi Chen, Graeme J Finlay, James A Kirker, et al.
Investigational New Drugs|August 18, 2010
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibodyGiorgio Zauli, Federica Corallini, Sonia Zorzet, et al.
Investigational New Drugs|June 5, 2010
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cellsQinjie Weng, Jun Zhang, Ji Cao, et al.
Investigational New Drugs|June 5, 2010
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitorMakiko Kobayashi, Ikuko Takahashi-Suzuki, Toshiyasu Shimomura, et al.
Investigational New Drugs|August 25, 2010
Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicitySeok Jin Kim, Kihyun Kim, Yong Park, et al.
Investigational New Drugs|August 25, 2010
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancerSung Sook Lee, Hei-Cheul Jeung, Hyun Cheol Chung, et al.
Pageof 372